

Docket No.: H00666.70000.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Tanida et al.

Serial No.:

09/700,817

Filing Date: For:

May 17, 1999 SOLID PREPARATIONS FOR ORAL ADMINISTRATION OF

GENE-RELATED DRUGS

Examiner:

R. Schnizer

Art Unit:

1635

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the day of

December, 2002.

June Watson

U.S. Patent and Trademark Office **BOX SEQUENCE** P.O. Box 2327 Arlington, VA 22202

RECEIVED

DEC 1 6 2002

STATEMENT UNDER 37 C.F.R. §1.821(f)

TECH CENTER 1600/2900

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicant encloses herewith the Sequence Listing on a computer readable diskette. Applicant's attorney states that the information recorded in the computer readable form is identical to the written Sequence Listing previously submitted and that the Sequence Listing contains no new matter.

Respectfully submitted, Tanida et al., Applicant

John R. Van Amsterdam, Reg. No. 40,212

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210 Telephone: (617) 720-3500


Docket No. H00666.70000.US Date: December 9, 2002

x12/14/02

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY